Skip to main content

Advertisement

SpringerLink
Log in

Central nervous system relapse in patients with diffuse large B cell lymphoma: analysis of the risk factors and proposal of a new prognostic model

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Central nervous system (CNS) relapse in patients with diffuse large B cell lymphoma (DLBCL) is an uncommon event, and the outcome of patients with CNS relapse is poor. However, no reliable prediction models for CNS relapse have been developed. We retrospectively analyzed consecutive de novo DLBCL patients referred to our department between September 2004 and August 2015 and treated with R-CHOP or R-CHOP-like regimens. Of 413 patients analyzed in this study, a total of 27 patients (6.5 %) eventually developed CNS relapse. The 5-year probability of CNS relapse was 8.4 %. The median time from diagnosis of DLBCL to CNS relapse was 15 months, and the median survival after CNS relapse was 7 months. In univariate analysis, the risk factors significantly associated with CNS relapse were Ann Arbor stage 3 or 4, albumin level <3.2 mg/L, number of extranodal sites >1, and involvement of retroperitoneal lymph node. We developed a new prognostic model consisting of these four factors. The 5-year probability of CNS relapse was significantly higher in patients with at least three of these four factors than in those with two or fewer factors (26.4 vs. 3.0 %, P < 0.001). Using this model, we evaluated the incidence and the risk factors of CNS relapse in DLBCL patients. The new risk model consisting of the four factors demonstrated good risk stratification for CNS relapse, and could help to identify high-risk patients for whom CNS prophylaxis is warranted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (2008) World Health Organization classification of tumours of haematopoietic and lymphoid tissues, 4th edn. France IARC Press, Lyon, pp 233–237

    Google Scholar 

  2. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346(4):235–242. doi:10.1056/NEJMoa011795

    Article  CAS  PubMed  Google Scholar 

  3. Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, Dakhil SR, Woda B, Fisher RI, Peterson BA, Horning SJ (2006) Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 24(19):3121–3127. doi:10.1200/jco.2005.05.1003

    Article  CAS  PubMed  Google Scholar 

  4. Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, Reiser M, Nickenig C, Clemens M, Peter N, Bokemeyer C, Eimermacher H, Ho A, Hoffmann M, Mertelsmann R, Trumper L, Balleisen L, Liersch R, Metzner B, Hartmann F, Glass B, Poeschel V, Schmitz N, Ruebe C, Feller AC, Loeffler M (2008) Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 9(2):105–116. doi:10.1016/s1470-2045(08)70002-0

    Article  CAS  PubMed  Google Scholar 

  5. Pfreundschuh M, Kuhnt E, Trumper L, Osterborg A, Trneny M, Shepherd L, Gill DS, Walewski J, Pettengell R, Jaeger U, Zinzani PL, Shpilberg O, Kvaloy S, de Nully BP, Stahel R, Milpied N, Lopez-Guillermo A, Poeschel V, Grass S, Loeffler M, Murawski N (2011) CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol 12(11):1013–1022. doi:10.1016/s1470-2045(11)70235-2

    Article  CAS  PubMed  Google Scholar 

  6. Feugier P, Virion JM, Tilly H, Haioun C, Marit G, Macro M, Bordessoule D, Recher C, Blanc M, Molina T, Lederlin P, Coiffier B (2004) Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Ann Oncol 15(1):129–133

    Article  CAS  PubMed  Google Scholar 

  7. Boehme V, Schmitz N, Zeynalova S, Loeffler M, Pfreundschuh M (2009) CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood 113(17):3896–3902. doi:10.1182/blood-2008-10-182253

    Article  CAS  PubMed  Google Scholar 

  8. Villa D, Connors JM, Shenkier TN, Gascoyne RD, Sehn LH, Savage KJ (2010) Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol 21(5):1046–1052. doi:10.1093/annonc/mdp432

    Article  CAS  PubMed  Google Scholar 

  9. Tomita N, Yokoyama M, Yamamoto W, Watanabe R, Shimazu Y, Masaki Y, Tsunoda S, Hashimoto C, Murayama K, Yano T, Okamoto R, Kikuchi A, Tamura K, Sato K, Sunami K, Shibayama H, Takimoto R, Ohshima R, Hatta Y, Moriuchi Y, Kinoshita T, Yamamoto M, Numata A, Ishigatsubo Y, Takeuchi K (2012) Central nervous system event in patients with diffuse large B-cell lymphoma in the rituximab era. Cancer Sci 103(2):245–251. doi:10.1111/j.1349-7006.2011.02139.x

    Article  CAS  PubMed  Google Scholar 

  10. Ferreri AJ, Bruno-Ventre M, Donadoni G, Ponzoni M, Citterio G, Foppoli M, Vignati A, Scarfo L, Sassone M, Govi S, Caligaris-Cappio F (2015) Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era. Br J Haematol 168(5):654–662. doi:10.1111/bjh.13194

    Article  CAS  PubMed  Google Scholar 

  11. Hollender A, Kvaloy S, Nome O, Skovlund E, Lote K, Holte H (2002) Central nervous system involvement following diagnosis of non-Hodgkin’s lymphoma: a risk model. Ann Oncol 13(7):1099–1107

    Article  CAS  PubMed  Google Scholar 

  12. Schmitz N, Zeynalova S, Nickelsen M, Ziepert M, Pfreundschuh M, Glass B, Loeffler M (2013) A new prognostic model to assess the risk of CNS disease in patients with aggressive B-cell lymphoma. Hematol Oncol 31(S1):96–150

    Article  Google Scholar 

  13. A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project (1993). N Eng J Med 329 (14):987-994. doi:10.1056/nejm199309303291402

  14. Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, Vanderplas A, Zelenetz AD, Abel GA, Rodriguez MA, Nademanee A, Kaminski MS, Czuczman MS, Millenson M, Niland J, Gascoyne RD, Connors JM, Friedberg JW, Winter JN (2014) An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood 123(6):837–842. doi:10.1182/blood-2013-09-524108

    Article  CAS  PubMed  Google Scholar 

  15. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25(5):579–586. doi:10.1200/jco.2006.09.2403

    Article  PubMed  Google Scholar 

  16. Tsurumi H, Hara T, Goto N, Kanemura N, Kasahara S, Sawada M, Yasuda I, Yamada T, Shimizu M, Takami T, Moriwaki H (2007) A phase II study of a THP-COP regimen for the treatment of elderly patients aged 70 years or older with diffuse large B-cell lymphoma. Hematol Oncol 25(3):107–114. doi:10.1002/hon.815

    Article  CAS  PubMed  Google Scholar 

  17. Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48(3):452–458. doi:10.1038/bmt.2012.244

    Article  CAS  PubMed  Google Scholar 

  18. Boehme V, Zeynalova S, Kloess M, Loeffler M, Kaiser U, Pfreundschuh M, Schmitz N (2007) Incidence and risk factors of central nervous system recurrence in aggressive lymphoma—a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL). Ann Oncol 18(1):149–157. doi:10.1093/annonc/mdl327

    Article  CAS  PubMed  Google Scholar 

  19. Arkenau HT, Chong G, Cunningham D, Watkins D, Agarwal R, Sirohi B, Trumper M, Norman A, Wotherspoon A, Horwich A (2007) The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma. Ann Oncol 18(3):541–545. doi:10.1093/annonc/mdl434

    Article  PubMed  Google Scholar 

  20. Yamamoto W, Tomita N, Watanabe R, Hattori Y, Nakajima Y, Hyo R, Hashimoto C, Motomura S, Ishigatsubo Y (2010) Central nervous system involvement in diffuse large B-cell lymphoma. Eur J Haematol 85(1):6–10. doi:10.1111/j.1600-0609.2010.01438.x

    CAS  PubMed  Google Scholar 

  21. Tai WM, Chung J, Tang PL, Koo YX, Hou X, Tay KW, Quek R, Tao M, Lim ST (2011) Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab. Ann Hematol 90(7):809–818. doi:10.1007/s00277-010-1150-7

    Article  CAS  PubMed  Google Scholar 

  22. Bernstein SH, Unger JM, Leblanc M, Friedberg J, Miller TP, Fisher RI (2009) Natural history of CNS relapse in patients with aggressive non-Hodgkin’s lymphoma: a 20-year follow-up analysis of SWOG 8516—the Southwest Oncology Group. J Clin Oncol 27(1):114–119. doi:10.1200/jco.2008.16.8021

    Article  PubMed  PubMed Central  Google Scholar 

  23. Bjorkholm M, Hagberg H, Holte H, Kvaloy S, Teerenhovi L, Anderson H, Cavallin-Stahl E, Myhre J, Pertovaara H, Ost A, Nilsson B, Osby E (2007) Central nervous system occurrence in elderly patients with aggressive lymphoma and a long-term follow-up. Ann Oncol 18(6):1085–1089. doi:10.1093/annonc/mdm073

    Article  CAS  PubMed  Google Scholar 

  24. Haioun C, Besson C, Lepage E, Thieblemont C, Simon D, Rose C, Tilly H, Sonet A, Lederlin P, Attal M, Briere J, Reyes F (2000) Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin’s lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Groupe d’Etudes des Lymphomes de l’Adulte. Ann Oncol 11(6):685–690

    Article  CAS  PubMed  Google Scholar 

  25. Shimazu Y, Notohara K, Ueda Y (2009) Diffuse large B-cell lymphoma with central nervous system relapse: prognosis and risk factors according to retrospective analysis from a single-center experience. Int J Hematol 89(5):577–583. doi:10.1007/s12185-009-0289-2

    Article  CAS  PubMed  Google Scholar 

  26. van Besien K, Ha CS, Murphy S, McLaughlin P, Rodriguez A, Amin K, Forman A, Romaguera J, Hagemeister F, Younes A, Bachier C, Sarris A, Sobocinski KS, Cox JD, Cabanillas F (1998) Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood 91(4):1178–1184

    Google Scholar 

  27. Abramson JS, Hellmann M, Barnes JA, Hammerman P, Toomey C, Takvorian T, Muzikansky A, Hochberg EP (2010) Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer 116(18):4283–4290. doi:10.1002/cncr.25278

    Article  PubMed  Google Scholar 

  28. Kumar A, Vanderplas A, LaCasce AS, Rodriguez MA, Crosby AL, Lepisto E, Czuczman MS, Nademanee A, Niland J, Gordon LI, Millenson M, Zelenetz AD, Friedberg JW, Abel GA (2012) Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database. Cancer 118(11):2944–2951. doi:10.1002/cncr.26588

    Article  CAS  PubMed  Google Scholar 

  29. Chihara D, Oki Y, Matsuo K, Onoda H, Taji H, Yamamoto K, Morishima Y (2011) Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: analyses with competing risk regression model. Leuk Lymphoma 52(12):2270–2275. doi:10.3109/10428194.2011.596966

    Article  CAS  PubMed  Google Scholar 

  30. Ghose A, Elias HK, Guha G, Yellu M, Kundu R, Latif T (2015) Influence of rituximab on central nervous system relapse in diffuse large B-cell lymphoma and role of prophylaxis—a systematic review of prospective studies. Clin Lymphoma Myeloma Leuk 15(8):451–457. doi:10.1016/j.clml.2015.02.026

    Article  PubMed  Google Scholar 

  31. Zhang J, Chen B, Xu X (2014) Impact of rituximab on incidence of and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis. Leuk Lymphoma 55(3):509–514. doi:10.3109/10428194.2013.811239

    Article  CAS  PubMed  Google Scholar 

  32. Tomita N, Takasaki H, Ishiyama Y, Kishimoto K, Ishibashi D, Koyama S, Ishii Y, Takahashi H, Numata A, Watanabe R, Tachibana T, Ohshima R, Hagihara M, Hashimoto C, Takemura S, Taguchi J, Fujimaki K, Sakai R, Motomura S, Ishigatsubo Y (2015) Intrathecal methotrexate prophylaxis and central nervous system relapse in patients with diffuse large B-cell lymphoma following rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone. Leuk Lymphoma 56(3):725–729. doi:10.3109/10428194.2014.931953

    Article  CAS  PubMed  Google Scholar 

  33. Vitolo U, Chiappella A, Ferreri AJ, Martelli M, Baldi I, Balzarotti M, Bottelli C, Conconi A, Gomez H, Lopez-Guillermo A, Martinelli G, Merli F, Novero D, Orsucci L, Pavone V, Ricardi U, Storti S, Gospodarowicz MK, Cavalli F, Sarris AH, Zucca E (2011) First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. J Clin Oncol 29(20):2766–2772. doi:10.1200/jco.2010.31.4187

    Article  CAS  PubMed  Google Scholar 

  34. Cheah CY, Herbert KE, O’Rourke K, Kennedy GA, George A, Fedele PL, Gilbertson M, Tan SY, Ritchie DS, Opat SS, Prince HM, Dickinson M, Burbury K, Wolf M, Januszewicz EH, Tam CS, Westerman DA, Carney DA, Harrison SJ, Seymour JF (2014) A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma. Br J Cancer 111(6):1072–1079. doi:10.1038/bjc.2014.405

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Holte H, Leppa S, Bjorkholm M, Fluge O, Jyrkkio S, Delabie J, Sundstrom C, Karjalainen-Lindsberg ML, Erlanson M, Kolstad A, Fossa A, Ostenstad B, Lofvenberg E, Nordstrom M, Janes R, Pedersen LM, Anderson H, Jerkeman M, Eriksson M (2013) Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study. Ann Oncol 24(5):1385–1392. doi:10.1093/annonc/mds621

    Article  CAS  PubMed  Google Scholar 

  36. Zucca E, Conconi A, Mughal TI, Sarris AH, Seymour JF, Vitolo U, Klasa R, Ozsahin M, Mead GM, Gianni MA, Cortelazzo S, Ferreri AJ, Ambrosetti A, Martelli M, Thieblemont C, Moreno HG, Pinotti G, Martinelli G, Mozzana R, Grisanti S, Provencio M, Balzarotti M, Laveder F, Oltean G, Callea V, Roy P, Cavalli F, Gospodarowicz MK (2003) Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol 21(1):20–27

    Article  CAS  PubMed  Google Scholar 

  37. Cheah CY, Seymour JF (2015) Central nervous system prophylaxis in non-Hodgkin lymphoma: who, what, and when? Curr Oncol Rep 17(6):25. doi:10.1007/s11912-015-0450-4

    Article  PubMed  Google Scholar 

  38. Guirguis HR, Cheung MC, Mahrous M, Piliotis E, Berinstein N, Imrie KR, Zhang L, Buckstein R (2012) Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature. Br J Haematol 159(1):39–49. doi:10.1111/j.1365-2141.2012.09247.x

    Article  CAS  PubMed  Google Scholar 

  39. Kanungo A, Medeiros LJ, Abruzzo LV, Lin P (2006) Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis. Mod Pathol 19(1):25–33. doi:10.1038/modpathol.3800500

    Article  CAS  PubMed  Google Scholar 

  40. Le Gouill S, Talmant P, Touzeau C, Moreau A, Garand R, Juge-Morineau N, Gaillard F, Gastinne T, Milpied N, Moreau P, Harousseau JL, Avet-Loiseau H (2007) The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement. Haematologica 92(10):1335–1342. doi:10.3324/haematol.11305

    Article  PubMed  Google Scholar 

  41. Niitsu N, Okamoto M, Miura I, Hirano M (2009) Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations. Leukemia 23(4):777–783. doi:10.1038/leu.2008.344

    Article  CAS  PubMed  Google Scholar 

  42. Oki Y, Noorani M, Lin P, Davis RE, Neelapu SS, Ma L, Ahmed M, Rodriguez MA, Hagemeister FB, Fowler N, Wang M, Fanale MA, Nastoupil L, Samaniego F, Lee HJ, Dabaja BS, Pinnix CC, Medeiros LJ, Nieto Y, Khouri I, Kwak LW, Turturro F, Romaguera JE, Fayad LE, Westin JR (2014) Double hit lymphoma: the MD Anderson cancer center clinical experience. Br J Haematol 166(6):891–901. doi:10.1111/bjh.12982

    Article  CAS  PubMed  Google Scholar 

  43. Savage KJ, Johnson NA, Ben-Neriah S, Connors JM, Sehn LH, Farinha P, Horsman DE, Gascoyne RD (2009) MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood 114(17):3533–3537. doi:10.1182/blood-2009-05-220095

    Article  CAS  Google Scholar 

  44. Snuderl M, Kolman OK, Chen YB, Hsu JJ, Ackerman AM, Dal Cin P, Ferry JA, Harris NL, Hasserjian RP, Zukerberg LR, Abramson JS, Hochberg EP, Lee H, Lee AI, Toomey CE, Sohani AR (2010) B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol 34(3):327–340. doi:10.1097/PAS.0b013e3181cd3aeb

    Article  PubMed  PubMed Central  Google Scholar 

  45. Tomita N, Tokunaka M, Nakamura N, Takeuchi K, Koike J, Motomura S, Miyamoto K, Kikuchi A, Hyo R, Yakushijin Y, Masaki Y, Fujii S, Hayashi T, Ishigatsubo Y, Miura I (2009) Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations. Haematologica 94(7):935–943. doi:10.3324/haematol.2008.005355

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Savage KJ, Slack GW, Mottok A, Sehn LH, Villa D, Kansara R, Kridel R, Steidl C, Ennishi D, Tan KL, Ben-Neriah S, Johnson NA, Connors JM, Farinha P, Scott DW, Gascoyne RD (2016) The impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL. Blood. doi:10.1182/blood-2015-10-676700

    Google Scholar 

  47. Miyazaki K, Yamaguchi M, Suzuki R, Kobayashi Y, Maeshima AM, Niitsu N, Ennishi D, Tamaru JI, Ishizawa K, Kashimura M, Kagami Y, Sunami K, Yamane H, Nishikori M, Kosugi H, Yujiri T, Hyo R, Katayama N, Kinoshita T, Nakamura S (2011) CD5-positive diffuse large B-cell lymphoma: a retrospective study in 337 patients treated by chemotherapy with or without rituximab. Ann Oncol 22(7):1601–1607. doi:10.1093/annonc/mdq627

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We would like to thank all the patients who took part in this study.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo, Japan

    Yusuke Kanemasa, Tatsu Shimoyama, Miho Tamura, Takeshi Sawada, Yasushi Omuro & Yoshiharu Maeda

  2. Department of Clinical Research Support, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan

    Yuki Sasaki

  3. Department of Pathology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan

    Tsunekazu Hishima

Authors
  1. Yusuke Kanemasa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tatsu Shimoyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yuki Sasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Miho Tamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Takeshi Sawada
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yasushi Omuro
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tsunekazu Hishima
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yoshiharu Maeda
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yusuke Kanemasa.

Ethics declarations

Conflict of interest

The authors report that they have no conflict of interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kanemasa, Y., Shimoyama, T., Sasaki, Y. et al. Central nervous system relapse in patients with diffuse large B cell lymphoma: analysis of the risk factors and proposal of a new prognostic model. Ann Hematol 95, 1661–1669 (2016). https://doi.org/10.1007/s00277-016-2744-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-016-2744-5

Keywords

Search

Navigation